Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|
Aug. 31, 2018
USD ($)
Program
|
Jun. 30, 2020
$ / shares
|
Mar. 31, 2020
USD ($)
|
Jun. 30, 2019
$ / shares
|
Jun. 30, 2020
USD ($)
$ / shares
|
Jun. 30, 2019
USD ($)
$ / shares
|
Jun. 16, 2020 |
|||
Summary Of Significant Accounting Policies [Line Items] | |||||||||
Net income | $ (10,277) | $ 28,043 | |||||||
Net income (loss) per share, basic | $ / shares | [1] | $ 1.00 | $ (0.60) | $ 0.39 | $ (1.22) | ||||
Net income (loss) per share, diluted | $ / shares | [1] | $ 0.94 | $ (0.60) | $ 0.36 | $ (1.22) | ||||
Fair Value Measurements Recurring | Level 2 | Measurement Input Discount for Lack of Marketability | |||||||||
Summary Of Significant Accounting Policies [Line Items] | |||||||||
Alternative investment, measurement input | 5.4 | ||||||||
2018 Merck Agreement | |||||||||
Summary Of Significant Accounting Policies [Line Items] | |||||||||
Upfront payment received | $ 60,000 | ||||||||
Number of research programs | Program | 2 | ||||||||
Transaction price | $ 60,000 | ||||||||
Revenue recognized performance obligation | $ 47,100 | ||||||||
Number of target programs estimated service period | 3 years | ||||||||
Decrease in revenue due to adjustments | $ 3,600 | ||||||||
Net income | $ 3,600 | ||||||||
Net income (loss) per share, basic | $ / shares | $ 0.14 | ||||||||
Net income (loss) per share, diluted | $ / shares | $ 0.13 | ||||||||
|
X | ||||||||||
- Definition Decrease in revenue due to adjustments. No definition available.
|
X | ||||||||||
- Definition Number of research programs. No definition available.
|
X | ||||||||||
- Definition Number of target programs estimated service period. No definition available.
|
X | ||||||||||
- Definition Revenue performance obligation amounts recognized in revenues. No definition available.
|
X | ||||||||||
- Definition Summary of significant accounting policies. No definition available.
|
X | ||||||||||
- Definition Transaction price. No definition available.
|
X | ||||||||||
- Definition Upfront payment received. No definition available.
|
X | ||||||||||
- Definition Value of input used to measure alternative investment. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|